Menu Back toSESSION 6 : Development of Cell and Gene Therapy in Asia

5th DIA Cell and Gene Therapy Products Symposium in Japan

This event is now offered in a new entirely virtual format.

All prices are exclusive of 10% Japanese consumption tax

SESSION 6 : Development of Cell and Gene Therapy in Asia

Session Chair(s)

Sumimasa  Nagai, MD, PhD

Sumimasa Nagai, MD, PhD

  • Institute for Advancement of Clinical and Translational Science(iACT)
  • Kyoto University Hospital, Japan
Yoshie  Tsurumaki

Yoshie Tsurumaki

  • Group Manager, Cell & Gene Franchise
  • Novartis Pharma K.K., Japan


Hiroshi  Karasawa

Activity of APACRM WG1: Non-clinical

Hiroshi Karasawa

  • Cell Therapy Research Labs
  • Daiichi Sankyo Co.,Ltd., Japan
Toshimitsu  Tanaka

APACRM working group activity; WG2:Quality

Toshimitsu Tanaka

  • Senior Manager, CMC Regulatory Affairs
  • Astellas Pharma Inc., Japan
Yunhong  Huang

Development of Cell and Gene Therapy in China

Yunhong Huang

  • Center for Drug Evaluation, National Medical Products Administration, China
Yoshiaki  Maruyama, PhD

PMDA Perspective : Regulatory Convergence on Regenerative Medicine

Yoshiaki Maruyama, PhD

  • Review Director, Office of Cellular and Tissue-based Products
  • Pharmaceuticals and Medical Devices Agency (PMDA), Japan

Contact us

Please contact DIA Japan for further information.

Send Email